Single Sector Fund

Nikko AM Global Shares Fund

Join KiwiSaver Invest Now

About the fund

The Nikko AM  Europe team manages this fund,  investing in a selection of around 40-50 companies from around the world, covering a diverse range of regions and sectors. The  manager selects companies where they believe there is potential for quality and future value.

 

 

Morningstar Bronze Rating Report 

mstar_bronze

Download Morningstar's managed investment report on the Nikko AM Global Shares Fund

 

Risk Indicator (volatility)

1
2
3
4
5 High
6
7

Target Asset Allocation

Growth 100.00%

Find out more about the Global Shares Fund from Iain Fulton

Iain is a Portfolio Manager within the Global Equity Team based in Edinburgh. In this video, Ian explains his global investment philosophy, the objectives of this portfolio, and the concept of future quality. Iain also talks us through the long term focus on sustainability and what's personally satisfying about doing what he does. Find out more about the Global Shares Fund from Iain Fulton in the video now.

Commentary

As of 31 May 2025

Market Overview

  • Markets extended their recovery in May, building on April’s lows as consumer sentiment improved and trade tensions eased.
  • Progress in U.S. trade negotiations with the European Union (EU) and a temporary delay to planned tariff hikes reduced fears of a global recession and fuelled broad-based gains across risk assets, with global indices rising more than 5% over the month.
  • The Information Technology (IT) sector was the best-performing sector. The underperforming sectors were either commodity-based or defensive in nature, with Healthcare being the only sector to post negative returns.

Fund Commentary

As a result of actions taken over the last 12 months, we are significantly underweight in IT, though the IT stocks we do own have a high beta. We also remain overweight in the Consumer Discretionary and Healthcare sectors. The portfolio is diversified - only slightly overweight in the U.S. and continues to be well-positioned to handle ongoing volatility. As always, we intend for stock selection to be the key driver of future returns. Amid the policy upheaval, we continue to search for - and find - new Future Quality ideas.

 

Contributors: Curtiss-Wright Corporation rose over 25% in May, driven by robust Q1 2025 results and an upgraded full-year outlook. The company reported a 13% year-over-year increase in sales to US Dollar 806 million and a surge in adjusted earnings. Strong demand across the Aerospace & Defense and commercial nuclear markets, along with operational strength in the Defense Electronics segment, contributed to this outperformance. Notably, Curtiss-Wright secured record new orders exceeding US Dollar 1 billion, reflecting a 1.26x book-to-bill ratio. Broadcom Inc. continued its strong performance in May, supported by solid fundamentals and investor optimism around AI and connectivity trends. Its diversified exposure to data centers, telecom, and industrial automation, combined with leadership in analog and mixed-signal semiconductors, positions Broadcom to benefit from AI proliferation across sectors. Palomar Holdings Inc. impressed investors with its Q1 2025 results, reporting strong net income growth and EPS of US Dollar 1.87. The specialty insurer’s robust underwriting performance and disciplined risk management supported earnings growth, while its diversified portfolio, spanning earthquake, flood, and hurricane insurance, provided resilience.

 

Detractors: Despite reporting solid Q1 2025 results, Genpact Limited’s stock underperformed in May due to tempered forward guidance caused by potential delays in several large client contracts. The company posted 8.3% year-over-year revenue growth, with strong performance in its Data-Tech-AI segment, which grew 11.7%. Elevance Health Inc. delivered strong Q1 2025 results, with revenue up 15.4% to US Dollar 48.8 billion and adjusted EPS of US Dollar 12. However, the stock lagged in May due to concerns around rising Medicare Advantage medical costs, following a profit warning from peer UnitedHealthcare. While Bio-Techne Corporation highlighted improved pharma end-market conditions and strong execution in Protein Sciences, sentiment toward Life Science Tools remains poor. U.S. government biotech funding remains in question, and potential drug price cuts continue to undermine biotech investor confidence. 

Performance

Nikko AM Investment Scheme
Open Close

Performance

at 31 May 2025
One month Three months One year Three years (p.a) Five years (p.a)
Fund performance1 6.50% -1.15% 20.87% 14.94% 14.06%
Appropriate Market Index (AMI)2 5.11% -3.78% 16.95% 15.58% 14.20%
  1. Returns are before tax and after the deduction of fees and expenses and including tax credits (if any).
  2. AMI: MSCI ACWI, with net dividends reinvested unhedged in NZD.

5 year cumulative performance $10,000 invested

Top 10 Holdings

Security Name Percentage
Microsoft Corp 5.75%
Nvidia Corp 4.93%
Amazon Com Inc 4.41%
Meta Platforms Inc 4.18%
Netflix Inc 3.34%
Broadcom Corp Com 2.96%
HDFC Bank Ltd 2.93%
Coca-Cola Europacific Partners 2.84%
Intercontinental Exchange Inc 2.80%
Haleon Plc 2.72%
Get the GoalsGetter Guide to Managed Funds

Get the GoalsGetter Guide to Managed Funds

If you've got a sum of money burning a hole in your pocket, it's time to put that money to work to meet your financial goals. But where to start? In this guide, we cover the fundamentals of investing in managed funds.